Feature | January 23, 2014

Nanotherapy Advancement May Help Reduce Recurrent Heart Attacks and Stroke

HDL nanoparticle delivers statin medication to inflamed blood vessels, prevents repeat heart attacks, stroke

January 23, 2014 — Up to 30 percent of heart attack patients suffer an additional heart attack because of limited ability to control inflammation inside heart arteries that leads to clots rupturing and myocardial infarction or stroke.
 
An international research team, led by Icahn School of Medicine at Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.
 
HDL nanotherapy could potentially avert repeat heart attacks and may also reduce recurrent strokes caused by clots in brain arteries. 
 
The nanoparticles resemble HDL cholesterol particles and bind to the same receptors as natural HDL in order to deliver the statin drug. Oral statin medications work primarily in the liver to reduce levels of unhealthy lipids circulating in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost macrophages that hide in plaque in arterial walls. Researchers sought to bolster this anti-inflammatory function in their HDL nanotherapy design.
 
 “Levels of inflammation spike after a heart attack, which is why up to 30 percent of heart attack patients may suffer another heart attack, some while in hospital or just after discharge,” said co-author Zahi Fayad, Ph.D., professor of radiology and director of the Translational and Molecular Imaging Institute at Icahn.
 
According to Mount Sinai researchers, the best way to use their HDL nanotherapy is by injection after the clot that produces a heart attack or stroke has been treated. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response.
“Our study also confirms that the HDL nanoparticle is not seen as a foreign invader by the body’s immune system and that it has an inherent and natural affinity to target plaque macrophages,” said first author Jun Tang, Ph.D, M.S.
 
The team intends to conduct a clinical trial to test the HDL nanotherapy on humans. 
 
For more information: www.mountsinai.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init